New positive data presented for Janssen’s ponesimod remains questionable

multiple sclerosis
According to GlobalData, ponesimod is expected to be launched in the US in 2020 and it will become the third-in-class S1P receptor modulator behind Gilenya (fingolimod) and ozanimod.